Merck announces interim analysis from V710 Phase II/III trial in S. aureus infection

Download PDF Copy

Editorial Checklist

Reviewed

MerckApr 11 2011

NewsGuard 100/100 Score

Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Intercell AG (VSE: ICLL) today announced that following a pre-specified interim analysis from the Phase II/III clinical trial evaluating V710, an investigational vaccine for the prevention of Staphylococcus aureus (S. aureus) infection, the independent Data Monitoring Committee (DMC) recommended suspension of enrollment. Although the trial did not meet the pre-specified futility criteria, the DMC nonetheless recommended suspension of enrollment pending further analyses of the benefit/risk profile of the vaccine candidate. Merck and Intercell plan to provide a further update when analyses have been completed.

Source:

Posted in: Drug Trial News | Disease/Infection News

Tags: Antibody, Biotechnology, Bone, Clinical Trial, Encephalitis, Hepatitis C, Hospital, Influenza, Monoclonal Antibody, Pandemic, Staphylococcus aureus, Vaccine

Comments (0)

Download PDF Copy

Suggested Reading

New vaccine shows potential in preventing recurrence of triple-negative breast cancer

New vaccine shows potential in preventing recurrence of triple-negative breast cancer

Pfizer-BioNTech vaccine provides strong protection against MIS-C in children aged 5–17

Pfizer-BioNTech vaccine provides strong protection against MIS-C in children aged 5–17

Innovative vaccine shields livestock from four strains of foot and mouth disease

Innovative vaccine shields livestock from four strains of foot and mouth disease

Community partnerships lead to more inclusive health care for neurodiverse individuals

Community partnerships lead to more inclusive health care for neurodiverse individuals

New nasal vaccine could help stop the spread of whooping cough

New nasal vaccine could help stop the spread of whooping cough

Argonne receives $21.7 million to advance cancer and vaccine discoveries

Argonne receives $21.7 million to advance cancer and vaccine discoveries

Cleveland Clinic presents new findings on triple-negative breast cancer vaccine

Cleveland Clinic presents new findings on triple-negative breast cancer vaccine

Early RSV vaccination in pregnancy provides best protection for newborns

Early RSV vaccination in pregnancy provides best protection for newborns

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Public trust in COVID-19 vaccine science influences vaccine uptake in the US